Jeremy Skillington, CEO of Poolbeg Pharma #POLB discusses a major milestone being reached as POLB 001 achieves regulatory approval to commence its Lipopolysaccharide (LPS) human challenge clinical trial.
Key Highlights
• Clinical trial activities will formally commence on 22 July 2022
• The trial will assess the efficacy of POLB 001 in dampening the robust immune response to LPS which acts as a surrogate for the hyperinflammatory response associated with severe influenza and other diseases
• Start of the trial demonstrates significant delivery on commitment at IPO
• Initial results expected in Q4 2022 at which point the Company intends to rapidly monetise by out-licensing / partnering with pharma and biotech companies for further development of POLB 001
• Trial success would also pave the way for potential applications beyond severe influenza
To read the full RNS click here